Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats

Pharmaceutical Research

Volumn 29, Issue 4, 2012, Pages 1078-1086

  Cao, Yanguang ^a   Gao, Wei ^a,b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b PFIZER INC   (United States)

Author keywords

Glucagon like peptide 1; Glucose; Incretin; Insulin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD SAMPLING; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STEADY STATE;

ANIMALS; BINDING SITES; BLOOD GLUCOSE; DRUG ADMINISTRATION ROUTES; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INSULIN; KINETICS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84862681117     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0652-x     Document Type: Article

References (39)

1. Cefalu WT. The physiologic role of incretin hormones: clinical applications. J Am Osteopath Assoc. 2010;110(3 Suppl 2):S8-S14.
2. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy. 2010;30 (6):609-24.
3. Siddiqui NI. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J. 2009;18(1):113-24.
4. Torekov SS, Kipnes MS, Harley RE, Holst JJ, and Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab 2011.
5. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50(5):583-9.
6. Parkes DG, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Develop Res. 2001;53(4):260-7.
7. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56(4):406-19.
8. Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther. 2004;76(1):27-37.
9. Adair GS. The hemoglobin system. VI. The oxygen dissociation curve of hemoglobin. J Biol Chem. 1925;63:529-45.
10. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
11. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654-62.
12. Raman M, Radziuk J, Hetenyi Jr G. Distribution and kinetics of glucose in rats analyzed by noncompartmental and compartmental analysis. Am J Physiol. 1990;259(2 Pt1):E292-303.
13. Gopalakrishnan M, Suarez S, Hickey AJ, Gobburu JV. Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J Pharmacokinet Pharmacodyn. 2005;32(3-4):485-500.
14. Buchanan TA, Sipos GF, Gadalah S, Yip KP, Marsh DJ, Hsueh W, et al. Glucose tolerance and insulin action in rats with renovascular hypertension. Hypertension. 1991;18(3):341-7.
15. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A. 2007;104(3):937-42.
16. Gao W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther. 2011;336(3):881-90.
17. Gries JM, Munafo A, Porchet HC, Verotta D. Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J Pharmacol Exp Ther. 1999;289(1):371-7.
18. Marino MT, Costello D, Baughman R, Boss A, Cassidy J, Damico C, et al. Pharmacokinetics and pharmacodynamics of inhaled GLP- 1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ther. 2010;88(2):243-50.
19. Mentlein R, Dipeptidyl-peptidase IV. (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9-24.
20. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271(9):E458-64.
21. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220-4.
22. Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther. 2006;319(3):1297-306.
23. Gedulin BR, Smith PA, Jodka CW, Chen K, Bhavsar S, Nielsen LL, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356(1-2):231-8.
24. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2 (8571):1300-4.
25. Chan HB, Jain R, Ahrén B, Pacini G, D'Argenio DZ. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1126-33.
26. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman L, et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol. 2010;78(3):456-65.
27. Mann R, Nasr N, Hadden D, Sinfield J, Abidi F, Al-Sabah S, et al. Peptide binding at the GLP-1 receptor. Biochem Soc T. 2007;35 (Pt 4):713-6.
28. Knudsenand LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol. 1996;318(2-3):429-35.
29. Balkanand X, Li B. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol-Reg I. 2000;279(4):R1449-54.
30. Ionut V, Liberty IF, Hucking K, Lottati M, Stefanovski D, Zheng D, et al. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol Endocrinol Metab. 2006;291(4):E779-85.
31. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010;59(6):1330-7.
32. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, Lustig RH, Cashion AK, Burghen GA. Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord. 2003;27(11):1359-64.
33. Knop FK, Vilsboll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007;50(4):797-805.
34. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.Diabetes. 2008;57(5):1340-8.
35. Burcelinand S, Dejager R. GLP-1: what is known, new and controversial in 2010? Diabetes Metab. 2010;36(6 pt 1):503-9.
36. D'Alessio D, Lu W, Sun W, Zheng S, Yang Q, Seeley R, et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Comp Physiol. 2007;293(6):R2163-9.
37. Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, et al. Pharmacokinetics and pharmacodynamic effects of oral GLP- 1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther. 2008;84(4):468-74.
38. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007;46(7):577-88.
39. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39(12):1546-53.